# US 2012/0252813 A1 · Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252813 A1
- Document ID: US20120252813A1
- Status: Published application
- Kind: A1
- Application number: 13/516,646
- Filed: 2010-12-16
- Published: 2012-10-04
- Earliest claimed: 2009-12-18
- Assignees: Arena Pharmaceuticals, Inc.
- Inventors: Scott Stirn; Edward A. Lally
- Web page: https://patentgrep.com/patent/US20120252813A1

## CPC

- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/30: for treating abuse or dependence
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are certain solvates of 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions comprising such solvates and methods for their use.

## Claims

### Claim 1

A solvate of 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide or a pharmaceutically acceptable salt thereof that is 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate.

### Claim 2

A solvate of 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide or a pharmaceutically acceptable salt thereof that is (4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a solvate of claim 1 and at least one pharmaceutically acceptable carrier.

### Claim 4 (depends on 2)

A pharmaceutical composition comprising a solvate of claim 2 and at least one pharmaceutically acceptable carrier.

### Claim 5 (depends on 1)

A method of treating a 5HT2A-related disorder comprising administering to a patient in need thereof a therapeutically effective amount of a solvate of claim 1.

### Claim 6 (depends on 5)

The method according to claim 5 wherein the 5HT2A-related disorder is selected from platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, sleep disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy.

### Claim 7 (depends on 6)

The method according to claim 6 wherein the 5HT2A-related disorder is a condition associated with platelet aggregation.

### Claim 8 (depends on 3)

A method of treating a 5HT2A-related disorder comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 3.

### Claim 9 (depends on 8)

The method according to claim 8 wherein the 5HT2A-related disorder is selected from platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, sleep disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy.

### Claim 10 (depends on 9)

The method according to claim 9 wherein the 5HT2A-related disorder is a condition associated with platelet aggregation.

### Claim at position 11

-21. (canceled)

### Claim 22 (depends on 2)

A method of treating a 5HT2A-related disorder comprising administering to a patient in need thereof a therapeutically effective amount of a solvate of claim 2.

### Claim 23 (depends on 22)

The method according to claim 22 wherein the 5HT2A-related disorder is selected from platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, sleep disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy.

### Claim 24 (depends on 23)

The method according to claim 23 wherein the 5HT2A-related disorder is a condition associated with platelet aggregation.

### Claim 25 (depends on 4)

A method of treating a 5HT2A-related disorder comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 4.

### Claim 26 (depends on 25)

The method according to claim 25 wherein the 5HT2A-related disorder is selected from platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, sleep disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy.

### Claim 27 (depends on 26)

The method according to claim 26 wherein the 5HT2A-related disorder is a condition associated with platelet aggregation.

### Claim 28

A process for preparing 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate comprising:
adding aqueous base to a solution of 4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium chloride; and
collecting the 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate.

### Claim 29 (depends on 28)

3-Methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate prepared by the process of claim 28.

### Claim 30

A process for preparing a pharmaceutical composition comprising 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate, said process comprising:
formulating a therapeutically effective amount of 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate and at least one pharmaceutically acceptable carrier to produce a pharmaceutical composition.

### Claim 31 (depends on 28, 30)

The process of claim 30, wherein the 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate is prepared by the process of claim 28.

### Claim 32 (depends on 30)

A pharmaceutical composition prepared by the process of claim 30.

### Claim 33

A process for preparing (4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate comprising:
adding ethanol and oxalic acid to 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide; and
collecting the (4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate.

### Claim 34 (depends on 33)

(4-(2-(4-(3-Methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate prepared by the process of claim 33.

### Claim 35

A process for preparing a pharmaceutical composition comprising (4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate, said process comprising:
formulating a therapeutically effective amount of (4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate and at least one pharmaceutically acceptable carrier to produce a pharmaceutical composition.

### Claim 36 (depends on 33, 35)

The process of claim 35, wherein the 4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate is prepared by the process of claim 33.

### Claim 37 (depends on 35)

A pharmaceutical composition prepared by the process of claim 35.

### Claim 38

A process for preparing a pharmaceutical composition comprising 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate, said process comprising:
admixing a therapeutically effective amount of 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate and at least one pharmaceutically acceptable carrier to produce a pharmaceutical composition.

### Claim 39 (depends on 28, 38)

The process of claim 38, wherein the 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide hydrate is prepared by the process of claim 28.

### Claim 40 (depends on 38)

A pharmaceutical composition prepared by the process of claim 38.

### Claim 41

A process for preparing a pharmaceutical composition comprising (4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate, said process comprising:
admixing a therapeutically effective amount of (4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate and at least one pharmaceutically acceptable carrier to produce a pharmaceutical composition.

### Claim 42 (depends on 33, 41)

The process of claim 41, wherein the 4-(2-(4-(3-methoxybenzamido)-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)ethyl)morpholin-4-ium carboxyformate ethanol solvate is prepared by the process of claim 33.

### Claim 43 (depends on 41)

A pharmaceutical composition prepared by the process of claim 41.
